Literature DB >> 9756762

Stability of cephalosporin prodrug esters in human intestinal juice: implications for oral bioavailability.

K Stoeckel1, W Hofheinz, J P Laneury, P Duchene, S Shedlofsky, R A Blouin.   

Abstract

The levels of degradation of cefetamet pivoxil (CAT), cefuroxime axetil (CAE), and cefpodoxime proxetil (CPD) in 0.6 M phosphate buffer (pH 7.4) and human intestinal juice (pH 7.4) at 37 degreesC over 24 h were compared. Significant differences in the time courses of degradation and in the patterns of degradation products were observed. (i) The relative proportions of the Delta2- and Delta3-cephalosporins were roughly reversed in the two incubation media. In phosphate buffer, the major degradation product was the Delta2-cephalosporin (CAT = 61%; CAE = 74%; CPD = 85%), while in intestinal juice it was the Delta3-cephalosporin (CAT = 86%; CAE = 75%; CPD = 87%). (ii) Generally, the degradation of the prodrug esters progressed faster in intestinal juice than in phosphate buffer (e.g., for CAT the half-lives [t1/2s] were 0.78 and 4.3 h, respectively). (iii) The two diastereoisomers of CAE and CPD were degraded at different rates in intestinal juice (for the CAE diasteroisomers, t1/2s = 0.37 and 0.93 h; for the CPD diastereoisomers, t1/2s = 0.18 and 0.98 h) but were degraded at similar rates in phosphate buffer (for the CAE diastereoisomers, t1/2 = 1.6 h; for the CPD t1/2 diastereoisomers, = 2.2 h). It is concluded that (i) the Delta2 isomerization does not significantly affect the bioavailability of prodrug esters since enzymatic hydrolysis in the intestinal fluid proceeds mainly to the active Delta3-cephalosporin and (ii) the high degree of stereoselectivity of the enzymatic ester hydrolysis should make it possible to increase the bioavailabilities of certain prodrug esters (CAE, CPD) by using the more stable diasterioisomer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9756762      PMCID: PMC105904     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Esterase activity toward the diastereomers of cefuroxime axetil in the rat and dog.

Authors:  G L Mosher; J McBee; D B Shaw
Journal:  Pharm Res       Date:  1992-05       Impact factor: 4.200

2.  On the mechanism of isomerization of cephalosporin esters.

Authors:  W F Richter; Y H Chong; V J Stella
Journal:  J Pharm Sci       Date:  1990-02       Impact factor: 3.534

3.  Isomerization of cephalosporin esters: implications for the prodrug ester approach to enhancing the oral bioavailabilities of cephalosporins.

Authors:  A N Saab; L W Dittert; A A Hussain
Journal:  J Pharm Sci       Date:  1988-10       Impact factor: 3.534

Review 4.  Clinical pharmacokinetics of oral cephalosporins.

Authors:  K Stoeckel; W L Hayton; D J Edwards
Journal:  Antibiot Chemother (1971)       Date:  1995

Review 5.  Microbiology of oral cephalosporins.

Authors:  W Cullmann
Journal:  Antibiot Chemother (1971)       Date:  1995

6.  Studies on orally active cephalosporin esters. IV. Effect of the C-3 substituent of cephalosporin on the gastrointestinal absorption in mice.

Authors:  M Miyauchi; T Hirota; K Fujimoto; J Ide
Journal:  Chem Pharm Bull (Tokyo)       Date:  1989-12       Impact factor: 1.645

7.  Synthesis and mechanisms of decomposition of some cephalosporin prodrugs.

Authors:  A N Saab; A A Hussain; I H Patel; L W Dittert
Journal:  J Pharm Sci       Date:  1990-09       Impact factor: 3.534

8.  Studies on orally active cephalosporin esters. II. Chemical stability of pivaloyloxymethyl esters in phosphate buffer solution.

Authors:  M Miyauchi; K Sasahara; K Fujimoto; I Kawamoto; J Ide; H Nakao
Journal:  Chem Pharm Bull (Tokyo)       Date:  1989-09       Impact factor: 1.645

9.  Purification and partial characterization of rat intestinal cefuroxime axetil esterase.

Authors:  C J Campbell; L J Chantrell; R Eastmond
Journal:  Biochem Pharmacol       Date:  1987-07-15       Impact factor: 5.858

  9 in total
  6 in total

1.  Enhancement of bioavailability of cefpodoxime proxetil using different polymeric microparticles.

Authors:  Fahim Khan; Rajesh Katara; Suman Ramteke
Journal:  AAPS PharmSciTech       Date:  2010-09-04       Impact factor: 3.246

Review 2.  The expanding role of prodrugs in contemporary drug design and development.

Authors:  Jarkko Rautio; Nicholas A Meanwell; Li Di; Michael J Hageman
Journal:  Nat Rev Drug Discov       Date:  2018-04-27       Impact factor: 84.694

3.  Enhancement of Dissolution Rate and Intestinal Stability of Clopidogrel Hydrogen Sulfate.

Authors:  Dina E Bali; Mohamed A Osman; Gamal M El Maghraby
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-12       Impact factor: 2.441

4.  Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).

Authors:  Pooja V Hegde; Michael D Howe; Matthew D Zimmerman; Helena I M Boshoff; Sachin Sharma; Brianna Remache; Ziyi Jia; Yan Pan; Anthony D Baughn; Veronique Dartois; Courtney C Aldrich
Journal:  Eur J Med Chem       Date:  2022-02-19       Impact factor: 6.514

5.  Synthesis, pH-dependent, and plasma stability of meropenem prodrugs for potential use against drug-resistant tuberculosis.

Authors:  Aaron M Teitelbaum; Anja Meissner; Ryan A Harding; Christopher A Wong; Courtney C Aldrich; Rory P Remmel
Journal:  Bioorg Med Chem       Date:  2013-05-24       Impact factor: 3.641

6.  Effect of C-2 substitution on the stability of non-traditional cephalosporins in mouse plasma.

Authors:  Matthew Zimmerman; Stacey L McDonald; Hsin-Pin Ho-Liang; Patrick Porubsky; Quyen Nguyen; Cameron W Pharr; Andrew J Perkowski; Robert Smith; Frank J Schoenen; Ben S Gold; David Zhang; Carl F Nathan; Véronique Dartois; Jeffrey Aubé
Journal:  J Antibiot (Tokyo)       Date:  2019-03-22       Impact factor: 2.649

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.